These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 63273)

  • 21. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An experimental model for evaluation of factors in tumor escape from immunological attack.
    Yutoku M; Fuji H; Grossberg AL; Pressman D
    Cancer Res; 1975 Mar; 35(3):734-9. PubMed ID: 1116132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice.
    Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G
    Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L; Fefer A
    Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract]   [Full Text] [Related]  

  • 25. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunochemical behaviour of a tumour-associated antigen obtained from an AKR mouse lymphoma.
    Hajos SE; Alvarez E; Pierangeli S; Margni RA; Pasqualini CD
    Vet Immunol Immunopathol; 1985 Jan; 8(1-2):157-69. PubMed ID: 3976168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phytohemagglutinin unresponsiveness of spleen cells of mice bearing an allogeneic lymphoma.
    Giraudo Conesa LC; Rumi L; Pasqualini CD
    Boll Ist Sieroter Milan; 1976 Sep; 55(4):308-10. PubMed ID: 1016584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E-rosette forming lymphocytes in thymus, lymph nodes and in tumor from mice bearing syngeneic or allogeneic lymphoma.
    Conesa LG; Pasqualini CD; Astaldi G
    Boll Ist Sieroter Milan; 1978 Sep; 57(4):458-63. PubMed ID: 737039
    [No Abstract]   [Full Text] [Related]  

  • 30. Correlation of "sneaking through" of tumor cells with specific immunological impairment of the host.
    Mengersen R; Schick R; Kölsch E
    Eur J Immunol; 1975 Aug; 5(8):532-7. PubMed ID: 61875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA; Ciavarra R; Riblet R; Forman J
    J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of antibody against mouse fetal antigen in the sera from C57BL-6 mice immunized with Rauscher leukemia.
    Ishimoto A; Ito Y
    Cancer Res; 1972 Nov; 32(11):2332-7. PubMed ID: 4343227
    [No Abstract]   [Full Text] [Related]  

  • 33. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
    Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological enhancement of a murine allogeneic tumor in absence of the spleen.
    Colmerauer ME; Pasqualine CD
    Cell Immunol; 1975 Dec; 20(2):327-9. PubMed ID: 1203990
    [No Abstract]   [Full Text] [Related]  

  • 35. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
    Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
    J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
    Clark DA; Gorczynski RM; Blajchman MA
    Transfusion; 2008 May; 48(5):814-21. PubMed ID: 18298594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
    Gjedde SB
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
    Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
    J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-thymocyte autoimmunity in BALB/C mice accompanying immunization to a syngeneic lymphoma.
    Baechtel FS; Prager MD
    J Immunol; 1977 Jan; 118(1):175-9. PubMed ID: 299754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.